Biomedical subjects

B G Johnson

Publications and source records attributed to B G Johnson.

At least 19 recordsLinked to original sources

PubMed1995

Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate.

Metabotropic glutamate receptors (mGluRs) are a heterogeneous family of G-protein coupled receptors that are linked to multiple second messengers in the rat hippocampus. The compound 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) has been widely used to activate this class of receptors and study their functions in situ. However, 1S,3R-ACPD acts on multiple mGluR subtypes to produce multiple alterations in second messengers. We report here that the aza-substituted analog of 1S,3R-ACPD, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC), is a highly selective agonist for negatively-coupled cAMP-linked mGluRs in the rat hippocampus, with similar potency in mGluR2 expressing cells. 1S,3R-ACPD decreases forskolin-stimulated cAMP formation, increases basal cAMP formation, and increases phosphoinositide hydrolysis in the rat hippocampus. However, 2R,4R-APDC inhibited forskolin-stimulated cAMP, but had none of the other activities of 1S,3R-ACPD. Furthermore, 2R,4R-APDC had no measurable ionotropic glutamate receptor affinity in rat hippocampus, as indicated by lack of effects on basal and glutamate agonist-evoked [3H]norepinephrine release. 2R,4R-APDC also inhibited forskolin-stimulated cAMP formation in human mGluR2 expressing cells with about three-fold greater potency than 1S,3R-ACPD, but unlike 1S,3R-ACPD, showed no appreciable activation of phosphoinostide hydrolysis in human mGluR1 alpha expressing cells. Thus, 2R,4R-APDC should be a useful pharmacological agent to explore the functions of mGluRs coupled to inhibition of adenylate cyclase.

Animals↗

PubMed1995

Second-messenger responses in brain slices to elucidate novel glutamate receptors.

G-Protein-coupled or 'metabotropic' glutamate receptors (mGluRs) are a novel heterogenous family of excitatory amino acid receptors. Activation of mGluRs in the rat hippocampus by the mGluR-selective agonist 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) leads to multiple changes in second-messenger formation. These include increases in basal phosphoinositide hydrolysis, decreases in forskolin-stimulated cAMP formation, and enhancement of cAMP formation via a potentiation of the effects of endogenous adenosine. These changes in mGluR coupling to phosphoinositide hydrolysis and the formation of cAMP likely reflect the in situ expression of heterogenous populations of mGluRs. A number of electrophysiological studies on the functions of mGluRs in hippocampal circuitry, ontogeny, and cellular functions have also been described. Any or all of these mGluR-mediated changes in second messengers may underlie the reported cellular effects associated with the mGluR activation by 1S,3R-ACPD. However, mGluR agonists that have selectivity for different mGluR second-messenger pathways are needed to sort out the cellular consequences of activating in situ expressed mGluR subtypes linked to specific second-messenger pathways.

Animals↗

PubMed1994

Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.

Structure-activity relationship studies were pursued within N-substituted-trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines in an effort to discover a peripherally selective opioid antagonist with high activity following systemic administration. Altering the size and the polarity of the N-substituent led to the discovery of 3 (LY246736). Compound 3 has high affinity for opioid receptors (Ki = 0.77, 40, and 4.4 nM for mu, kappa, and delta receptors, respectively). It is a potent mu receptor antagonist following parenteral and oral administration and distributes selectively (> 200-fold selectivity) to peripheral receptors. Thus, 3 has properties suitable for the clinical investigation of mu opioid receptor involvement in GI motility disorders.

Animals↗

PubMed1994

Disruption of potential alpha-helix in the G loop of the guinea pig 5-hydroxytryptamine2 receptor does not prevent receptor coupling to phosphoinositide hydrolysis.

Heterogeneity of the 5-hydroxytryptamine2 (5-HT2) receptor across species has been implicated in several pharmacological and physiological studies. Although 5-HT2 receptors in the rat have been linked to increases in phosphoinositide (PI) hydrolysis, little evidence exists to support the association of guinea pig 5-HT2 receptors with PI hydrolysis, the second messenger generally linked with 5-HT2 receptors. In the present study, we have taken a molecular and biochemical approach to determining whether species differences in brain 5-HT2 receptors exist between rat and guinea pig. First, we isolated partial cortical 5-HT2 receptor cDNA clones that encompassed the third intracellular loop, a receptor area putatively important in receptor-effector coupling. The amino acid sequences deduced from the cDNA clones for rat and guinea pig brain 5-HT2 receptor were 97% homologous. However, the guinea pig 5-HT2 receptor had two tandem substitutions that disrupted a potential alpha helix in the region of the third cytoplasmic loop, which theoretically could alter the intracellular coupling of the guinea pig cortical 5-HT2 receptor. Because of these molecular differences, we examined further the pharmacological activation of the brain 5-HT2 receptor from guinea pig. 5-HT and the 5-HT2 receptor agonist alpha-methyl-5-HT increased PI hydrolysis in guinea pig cortical slices whereas the 5-HT1C receptor agonist 5-methyltryptamine was significantly less potent. In addition, the 5-HT2 receptor antagonists LY53857, ketanserin, and spiperone blocked 5-HT-stimulated PI hydrolysis. These pharmacological data suggested that activation of the 5-HT2 receptor in guinea pig cortical slices was associated with PI hydrolysis. Thus, although areas of the guinea pig brain 5-HT2 receptor that influence receptor-effector coupling were different from the rat, such differences were not critical to receptor-effector coupling because, as in the rat, guinea pig brain 5-HT2 receptors were also coupled to PI hydrolysis.

Amino Acid Sequence↗

PubMed1994

3,5-dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus.

Metabotropic glutamate receptors (mGluRs) are a heterogeneous family of G protein-coupled glutamate receptors that are linked to multiple second messenger systems in the CNS. In this study the selectivity of mGluR agonists for different mGluR second messenger effects was characterized in slices of the rat hippocampus. The mGluR agonists (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid and (2S,3S,4S)alpha-(carboxycyclopropyl)glycine produced multiple effects on second messengers that included enhanced phosphoinositide hydrolysis in both adult and neonatal rat hippocampus, inhibition of forskolin-stimulated cyclic AMP (cAMP) formation in adult tissue, and increases in basal cAMP formation in the neonatal hippocampus. In contrast, 3,5-dihydroxyphenylglycine was potent and effective in increasing phosphoinositide hydrolysis in both adult and neonatal hippocampus but unlike the other mGluR agonists did not inhibit forskolin-stimulated cAMP formation (in the adult) or substantially enhance basal cAMP formation (in the neonate). Thus, in the rat hippocampus mGluR agonist-mediated increases or decreases in cAMP formation are not secondary to mGluR-mediated changes in phosphoinositide hydrolysis. Furthermore, 3,5-dihydroxyphenylglycine can be used to activate subpopulations of mGluRs coupled to phosphoinositide hydrolysis with minimal effects on cAMP-mGluR second messenger systems.

Aging↗

PubMed1994

Contractile serotonin-2A receptor signal transduction in guinea pig trachea: importance of protein kinase C and extracellular and intracellular calcium but not phosphoinositide hydrolysis.

Serotonin (5-HT) contracts the guinea pig trachea through stimulation of the 5-HT2A receptor, a receptor generally linked with phosphoinositide (PI) hydrolysis. However, previous limited evidence suggested that 5-HT did not increase PI hydrolysis in guinea pig trachea. The present studies confirmed that the 5-HT2A receptor is not coupled to PI hydrolysis and investigated the calcium source and involvement of protein kinase C (PKC) in 5-HT-induced contraction in guinea pig trachea. In vitro experiments, which used an enriched tracheal muscle preparation, confirmed the inability of 5-HT (10(-10) to 10(-2) M) to increase PI hydrolysis. Short incubations (1-60 min) of the trachea with 5-HT (10(-4) M) to minimize possible 5-HT2A receptor desensitization did not increase PI hydrolysis, whereas carbamylcholine (10(-7) to 10(-3) M) and histamine (10(-7) to 10(-4) M) did. These results demonstrate that, unlike most other 5-HT2A receptors, the 5-HT2A receptor in guinea pig trachea is not coupled to PI hydrolysis. The L-type calcium channel antagonists nitrendipine (10(-6) and 10(-5) M) and diltiazem (5 x 10(-5) M) significantly blocked maximal tracheal contraction to 5-HT (45-60%) inhibition) but not to carbamylcholine. The maximal response to 5-HT in calcium-free buffer (0 calcium, 0.05 mM EGTA) was also inhibited by 56%. The residual contraction to 5-HT in the absence of extracellular calcium suggested that at least a portion of the nitrendipine-insensitive 5-HT contraction was due to the release of intracellular calcium. In support of this idea, ryanodine (3 x 10(-5) M), a compound known to deplete intracellular calcium stores, depressed maximal 5-HT contraction in the presence of either nitrendipine or diltiazem. Neither calphostin C (4 x 10(-8) and 10(-6) M) or staurosporine (10(-8) M), both putative PKC inhibitors, affected tracheal contraction to 5-HT. However, the PKC inhibitor bisindolylmaleimide (5 x 10(-6) M), which abolished contraction to phorbol 12,13-dibutyrate (10(-6) M), unlike calphostin C, inhibited contraction to 5-HT in both the absence and presence of nitrendipine. This finding suggests that PKC activation is involved in 5-HT contraction. Thus, the tracheal 5-HT2A receptor is unique in that activation of the receptor does not result in PI hydrolysis but increases calcium influx through L-type voltage-dependent calcium channels, calcium release from the sarcoplasmic reticulum and activation of a bisindolylmaleimide-sensitive PKC.

Alkaloids↗

PubMed1993

Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.

A series of racemic N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines were evaluated for opioid agonist and antagonist activity at mu and kappa receptors. Several highly potent mu and kappa antagonists were discovered; however, no compounds with high selectivity for either the mu or kappa receptor were identified. Importantly, no derivative was found to have significant opioid agonist activity. Two derivatives were resolved, and the activities of the enantiomers were investigated. Only a limited stereochemical effect on opioid receptor selectivities was observed. The structure-activity relationships described establish the existence of an important lipophilic binding site distal to the nitrogen for both mu and kappa receptors and confirm the pure opioid antagonist pharmacophore nature of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine structure.

Analgesia↗

PubMed1993

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

A series of (3R*,4R*)-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists with varying substituents on the nitrogen were evaluated for their effect on food consumption in obese Zucker rats. Opioid affinity (mu, kappa, and delta for selected compounds) and opioid antagonist activity (mu and kappa) were characterized and compared to effects on food consumption. No compounds with high selectivity for either mu or kappa receptors were discovered. However, compounds in the series had exceptional potency as opioid antagonists and in reducing food consumption in the obese Zucker rat. In contrast, a few compounds with high potency as opioid antagonists had much weaker potency for inhibiting food consumption. (3R,4R)-3,4-Dimethyl-1-[(3S)-3- hydroxy-3-cyclohexyl-propyl]-4-(3-hydroxyphenyl)piperidine (11,LY255582) emerged as having the best activity profile, both in reducing food consumption and as an opioid antagonist. Compound 11 is a highly potent mu, kappa-, and delta-opioid antagonist with possible clinical utility as an appetite suppressant for weight loss.

Analgesia↗

PubMed1993

Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus.

The pharmacology and cellular mechanism by which metabotropic glutamate receptor (mGluR) activation modulates cAMP formation was studied in cross-chopped hippocampal slices from neonatal (7 day old) rats. The selective mGluR agonist 1S,3R-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD), and other non-selective mGluR agonists produced concentration-related stimulation of basal cAMP formation in this tissue. The relative agonist potency order was 1S,3R-ACPD = quisqualate > ibotenate >> 1R,3S-ACPD. 1S,3R-ACPD stimulated cAMP accumulation was antagonized in a stereoselective manner by L-2-amino-3-phosphonopropionate (L-AP3), but not by higher chain homologues such as L-2-amino-4-phosphonobutyrate (L-AP4) and 2-amino-5-phosphonopentanoate (AP5). 1S,3R-ACPD-enhanced cAMP formation was greatly inhibited by incubation with adenosine deaminase. In the adult rat hippocampus, 1S,3R-ACPD did not appreciably increase basal cAMP, but inhibited forskolin-stimulated cAMP formation, and this effect was observed with or without adenosine deaminase. In the presence of the adenosine receptor antagonist and cAMP phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine (IBMX), 1S,3R-ACPD did not enhance cAMP formation in the neonatal hippocampus, but inhibited forskolin-stimulated cAMP (like in the adult tissue). These results demonstrate that mGluRs that increase cAMP in the neonatal hippocampus have a unique pharmacology when compared to mGluRs that decrease cAMP accumulation and increase phosphoinositide hydrolysis. 1S,3R-ACPD stimulation of cAMP in the neonatal rat hippocampal slice involves potentiation of responses to endogenous adenosine. Negatively coupled cAMP linked mGluRs are also present in the neonatal tissue, but are masked by the predominance of the positively coupled mGluR cAMP response.

1-Methyl-3-isobutylxanthine↗

PubMed1993

Pharmacology of metabotropic glutamate receptor inhibition of cyclic AMP formation in the adult rat hippocampus.

Phosphoinositide-linked metabotropic glutamate receptors have been well characterized in a variety of CNS tissues. In this study the pharmacology of metabotropic glutamate receptors negatively coupled to cAMP formation was investigated in cross-chopped slices of the adult rat hippocampus. Excitatory amino acid agonists and antagonists were examined for effects on forskolin (30 microM)-simulated cAMP formation. The selective metabotropic glutamate agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) and various nonselective metabotropic/ionotropic agonists were found to inhibit forskolin-stimulated cAMP formation. Inhibition of cAMP formation was observed using 1S,3R-ACPD (57% at 100 microM), quisqualate (92% at 500 microM), ibotenate (44% at 500 microM), L-glutamate (41% at 1000 microM), and L-aspartate (59% at 1000 microM). Inhibition of forskolin-stimulated cAMP formation induced by these agonists was observed even in the presence of the ionotropic antagonists MK-801 and 6-cyano-7-nitroquinoxaline-2,3-dione. Up to 500 microM of the ionotropic agonists N-methyl-D-aspartate, AMPA, and kainate did not inhibit forskolin-stimulated cAMP formation. L-2-amino-3-phosphonopropionate (500 microM) greatly inhibited the stimulatory effect of 1S,3R-ACPD on phosphoinositide hydrolysis, even in the presence of forskolin. However when measuring cAMP formation, L-2-amino-3-phosphonoproprionate (500 microM) mimicked the effect of 1S,3R-ACPD, producing 64% inhibition of forskolin-stimulated cAMP. These studies show that in the adult rat hippocampus metabotropic glutamate receptors that are negatively linked to cAMP formation have a pharmacology that is distinct from ionotropic glutamate receptors and phosphoinositide-linked metabotropic glutamate receptors.

Alanine↗

PubMed1992

Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist.

It is well documented that the effects of excitatory amino acid (EAA) agonists on phosphoinositide hydrolysis involve a GTP-binding protein-linked or "metabotropic" receptor mechanism. The mechanisms by which EAAs alter cyclic AMP levels in brain slices, however, are not yet clear. In this study, the selective metabotropic EAA agonist trans-(+-)-1-aminocyclopentane-1,3-dicarboxylic acid and its isomers were examined for effects on basal and forskolin-stimulated cyclic AMP formation in slices of the rat hippocampus. Trans-(+-)-1-Aminocyclopentane-1,3-dicarboxylic acid had little effect on basal cyclic AMP but inhibited forskolin-stimulated cyclic AMP formation in a biphasic manner. The 1S,3R isomer of 1-aminocyclopentane-1,3-dicarboxylic acid produced potent but only partial (approximately 50%) inhibition of forskolin-stimulated cyclic AMP formation. 1R,3S-1-Aminocyclopentane-1,3-dicarboxylic acid fully inhibited forskolin-stimulated cyclic AMP but with lower potency than the 1S,3R isomer. These results show that in addition to the formation of phosphoinositide-derived second messengers, the cellular consequences of selectively activating hippocampal metabotropic EAA receptors include an alteration of cellular cyclic AMP levels.

Animals↗

PubMed1991

Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis.

(1S,3R)-1-Aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) and (1R,3S)-1-aminocyclopentane-1,3-dicarboxylic acid (1R,3S-ACPD) were characterized for potency, efficacy, and selectivity at metabotropic excitatory amino acid receptors. 1S,3R-ACPD stimulated [3H]phosphoinositide hydrolysis in slices of the neonatal and adult rat hippocampus with full efficacy and twice the potency relative to what has been shown for (+/-)-trans-ACPD. 1S,3R-ACPD was up to 30 times more potent in activating metabotropic excitatory amino acid receptors, compared to its affinity for [3H]CGS19755 binding to NMDA receptors. In contrast, 1R,3S-ACPD was much less potent, efficacious, and selective than 1S,3R-ACPD. Although 1S,3R-ACPD is not specific, it is a most selective and efficacious agonist at metabotropic excitatory amino acid receptors.

Animals↗

PubMed1991

In vitro and in vivo pharmacology of trans- and cis-(+-)-1-amino-1,3-cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects.

This study explored further the function of the metabotropic excitatory amino acid receptor in the rat brain. The trans and cis isomers of (+-)-1-amino-1,3-cyclopentane-dicarboxylic acid (ACPD) were characterized for relative affinities at ionotropic and metabotropic excitatory amino acid receptors in vitro, as well as ability to produce in vivo excitatory or excitotoxic effects in rats. trans-ACPD was about 12 times more potent in vitro as an agonist for metabotropic excitatory amino acid receptors when compared to its ability to displace N-methyl-D-aspartate (NMDA) ([3H]CGS-19755) receptor binding, cis-ACPD was about 30 times more potent as a displacer of [3H]CGS-19755 binding than as a stimulant of phosphoinositide hydrolysis. When administered intraperitoneally to neonatal rats, both cis- and trans-ACPD produced convulsions that were prevented by the competitive NMDA receptor antagonists, LY233053 and LY274614. cis-ACPD was six times more potent as a convulsant when compared to trans-ACPD. Both compounds were examined for excitotoxic effects in vivo following stereotaxic injection into the mature or neonatal rat striatum. Doses of trans-ACPD of up to 5,000 or 1,200 nmol produced few signs of striatal neuronal degeneration in the mature or neonatal brain, respectively. However, cis-ACPD produced extensive dose-related neuronal degeneration at doses of 100-1,000 nmol in the mature brain and 50-200 nmol in the neonatal brain. These studies suggest that, unlike the ionotropic excitatory amino acid receptors, activation of the metabotropic excitatory amino acid receptor does not result directly in excitatory effects, such as excitotoxicity.

Animals↗

PubMed1991

Neuromodulatory effect of the atrial natriuretic factor clearance receptor binding peptide, cANF(4-23)-NH2 in rabbit isolated vasa deferentia.

This study tests the hypothesis that atrial natriuretic factor (ANF) and the ANF clearance receptor binding peptide, cANF(4-23)-NH2 (cANF), inhibit adrenergic and purinergic neurotransmission in the rabbit isolated vas deferens by a pertussis toxin (PTX)-sensitive mechanism. The vas deferens is a unique model used in the study of autonomic neurotransmission inasmuch as it has both a purinergic or twitch contraction and an adrenergic or tonic contraction associated with its response to electrical stimulation. Both ANF and cANF (10(-11) to 10(-6) M) inhibited electrically induced purinergic and adrenergic contractile force generation in a concentration-dependent manner. The ANF effect on both purinergic and adrenergic contractions was blocked by PTX (100 ng/ml). The cANF effect on the adrenergic contraction was also PTX-sensitive. Both peptides also attenuated evoked norepinephrine release in a concentration-dependent manner by a PTX-sensitive mechanism. cANF (10(-7) M) had no effect on norepinephrine- or ATP-induced contractions as was shown previously for ANF (10(-7) M). Therefore, the inhibitory effects of ANF and cANF appear to be prejunctional, on the release of the neurotransmitters, norepinephrine and ATP, from the nerve terminal and not postjunctional on the smooth muscle. An effect of cANF on neurotransmission suggests that the reputed "silent" ANF clearance receptor has biological activity. PTX-sensitivity suggests the involvement of a guanine nucleotide-binding protein in mediating the neuromodulatory effect of atrial peptides.

Animals↗

PubMed1990

Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes.

We found that N-methyl-D-aspartate (NMDA) was a very potent, systematically active convulsant in the rat in the early period of postnatal development (7-11 days of age). Other receptor subtype-selective excitatory amino acid agonists were then examined for their convulsant effects following i.p. administration to neonatal rats. alpha-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) was the most potent convulsant (ED50 0.6 mg/kg), followed by kainate (ED50 1.5 mg/kg), N-methyl-D-aspartate (NMDA) (ED50 3.1 mg/kg), then quisqualate (ED50 5.1 mg/kg). NMDA-induced convulsions were antagonized in a dose-related manner by prior administration of the NMDA antagonists cis-(+/- )-4-phosphonomethyl-2-piperidine carboxylic acid (CGS19755), cis-(+/- )-4-(2H-tetrazol-5-yl)methyl-piperidine-2-carboxylic acid (LY233053), (+/- )3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), D,L-2-amino-5-phosphonovalerate (D,L-AP5) and MK801. NMDA antagonists did not protect against AMPA- or kainate-induced convulsions. 6,7-Dinitroquinoxaline-2,3-dione (DNQX) selectively prevented the effect of AMPA at doses which had no effect on NMDA or kainate convulsions. Quisqualate-induced convulsions were antagonized by NMDA antagonists or DNQX. The greater sensitivity of neonatal rats to systemically administered excitatory amino acid agonists appears useful for evaluating the selectivity of antagonists acting at ionotropic excitatory amino acid receptors in the central nervous system. Using neonatal rats three pharmacologically distinct excitatory amino acid receptor effects were demonstrated following administration of NMDA, AMPA or kainate.

Aging↗

PubMed1990

Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid.

DL-2-Amino-3-phosphonopropionic acid, a phosphonate-substituted derivative of aspartic acid, has been shown to be an inhibitor of excitatory amino acid-stimulated phosphoinositide hydrolysis in rat brain slices. In this study, the enantiomers of 2-amino-3-phosphonopropionic acid were synthesized and used to further characterize the stereoselectivity and mechanism of interaction of this compound for inhibiting phosphoinositide-coupled (metabotropic) excitatory amino acid receptors. L-2-Amino-3-phosphonopropionic acid was 3-5 times more potent than D-2-amino-3-phosphonopropionic acid as an inhibitor of ibotenate-stimulated [3H]inositol monophosphate formation in slices of the rat hippocampus or quisqualate-stimulated [3H]inositol monophosphate formation in neonatal rat cerebral cortical slices. Carbachol-stimulated phosphoinositide hydrolysis was not inhibited by L-2-amino-3-phosphonopropionic acid, and L-2-amino-3-phosphonopropionic acid had no appreciable affinity for ionotropic excitatory amino acid receptors at concentrations required to inhibit metabotropic excitatory amino acid responses. The inhibitory effects of L-2-amino-3-phosphonopropionic acid or L-2-amino-4-phosphonobutyric acid on phosphoinositide hydrolysis were not competitive, because they could not be surmounted by increasing concentrations of ibotenate or quisqualate. L-2-Amino-3-phosphonopropionic acid inhibition also could not be prevented by washing the tissue before incubation with ibotenate. Thus, L-2-amino-3-phosphonopropionic acid is a stereoselective inhibitor of metabotropic excitatory amino acid receptors with little affinity for ionotropic receptors. However, the inhibitory effects of L-2-amino-3-phosphonopropionic acid or L-2-amino-4-phosphonobutyric acid were not readily reversed, and the site at which they act to inhibit metabotropic excitatory amino acid receptors remains to be determined.

Alanine↗

PubMed1989

Comparison of excitatory amino acid-stimulated phosphoinositide hydrolysis and N-[3H]acetylaspartylglutamate binding in rat brain: selective inhibition of phosphoinositide hydrolysis by 2-amino-3-phosphonopropionate.

The activation of phosphoinositide hydrolysis by ibotenate (IBO) in brain slices and the binding of N-[3H]acetylaspartyl-L-glutamate (NAAG) to brain membranes are biochemical parameters previously shown to be selectively inhibited by 2-amino-4-phosphonobutyrate (AP4). We have examined whether the binding of [3H]NAAG and stimulation of phosphoinositide hydrolysis by IBO are indexing the same or different populations of AP4-sensitive excitatory amino acid sites in brain. L-AP4 and D,L-2-amino-3-phosphonopropionate (D,L-AP3) were found to be about equipotent inhibitors of IBO-stimulated phosphoinositide hydrolysis. L-AP4 and D,L-AP3 did not inhibit stimulation of phosphoinositide hydrolysis by the cholinoceptor agonist carbachol. The L-isomers of serine-O-phosphate and alpha-aminoadipate were selective inhibitors of IBO-stimulated phosphoinositide hydrolysis, but were less potent than L-AP4 or D,L-AP3. When these compounds were examined for their ability to inhibit [3H]NAAG binding to membranes of rat forebrain, the relative order of potency was L-alpha-aminoadipate = D-alpha-aminoadipate greater than L-AP4 greater than L-serine-O-phosphate greater than D-AP4 much greater than D,L-AP3. Concentrations of NAAG up to 10(-2) M did not stimulate phosphoinositide hydrolysis. Thus, although both assays are sensitive to L-AP4 inhibition, they appear to represent disparate excitatory amino acid sites in brain. Furthermore, D,L-AP3 appears to be a more selective inhibitor of excitatory amino acid-stimulated phosphoinositide hydrolysis than L-AP4, and might be a more useful pharmacological tool to define the function of these receptor sites in brain.

Alanine↗

PubMed1989

Inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the neonatal rat hippocampus by 2-amino-3-phosphonopropionate.

The effects of excitatory amino acid agonists and alpha-amino-omega-phosphonocarboxylic acid antagonists on phosphoinositide hydrolysis in hippocampal slices of the 7-day neonatal rat were examined. Significant stimulation of [3H]inositol monophosphate formation was observed with ibotenate, quisqualate, L-glutamate, L-aspartate, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, L-homocysteate, and kainate. N-Methyl-D-aspartate had no effect. Of these agonists, ibotenate and quisqualate were the most potent and efficacious. Stimulations by ibotenate and quisqualate were partially inhibited by L-2-amino-4-phosphonobutyrate (10(-3) M), but this antagonist had no effect on L-glutamate, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, or kainate. At 10(-3) M, D,L-2-amino-3-phosphonopropionate completely inhibited ibotenate and quisqualate stimulations, partially inhibited L-glutamate stimulation, and had no effect on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-, kainate-, or carbachol-induced [3H]inositol monophosphate formation. Concentration-effect experiments showed D,L-2-amino-3-phosphonopropionate to be five times more potent as an antagonist of ibotenate-stimulated phosphoinositide hydrolysis than L-2-amino-4-phosphonobutyrate. Thus in the neonatal rat hippocampus, like in the adult rat brain, D,L-2-amino-3-phosphonopropionate is a selective and relatively potent inhibitor of excitatory amino acid-stimulated phosphoinositide hydrolysis. Because this glutamate receptor is uniquely sensitive to D,L-2-amino-3-phosphonopropionate, these studies provide further pharmacological evidence for the existence of a novel excitatory amino acid receptor subtype that is coupled to phosphoinositide hydrolysis in brain.

Alanine↗